#United States #Grand Rapids #Clinical Trials #Headlands Research

Headlands Research Expands Midwest Presence with New Site

Headlands Research, a prominent network for clinical trials, has recently announced the establishment of a new research site in Grand Rapids, Michigan. This strategic move is set to boost the organization’s capacity in several therapeutic areas, particularly rheumatology and autoimmune diseases. The site, led by the esteemed Dr. Eric Slavin, who is board-certified in both rheumatology and internal medicine, aims to enhance the quality of research and patient care in the region.

Expanding Capabilities

The new Headlands Research - Grand Rapids site is part of a broader initiative to expand the company’s reach in the Midwest, an area where there is a growing demand for clinical trials in therapeutic areas such as rheumatology, bone and joint conditions, and autoimmune diseases. According to Kyle Burtnett, CEO of Headlands Research, the organization's mission is to become the partner of choice for sponsors and Contract Research Organizations (CROs) by providing access to knowledgeable investigators and engaged patient populations.

"Dr. Slavin brings exceptional clinical expertise and a deep commitment to his patients, which is crucial as we aim to meet the increasing sponsor demand in rheumatology and autoimmune diseases," Burtnett stated.

The facility is expected to open its doors later this year, and it will not only focus on rheumatology but also work on various studies spanning general medicine, cardiometabolic diseases, chronic kidney diseases, obesity, hypertension, hyperlipidemia, and vaccines. This comprehensive research capability is expected to serve the Grand Rapids community effectively.

Commitment to Quality Care

Dr. Slavin, who has an extensive background in clinical trials, particularly in evaluating innovative therapies for rheumatoid arthritis and other autoimmune conditions, is excited about the opportunity presented by the new site. His involvement in multiple Phase III and IV clinical trials showcases his substantial experience, including work with biologic and targeted disease-modifying treatments.

"I am thrilled to join Headlands and provide our research capabilities to the Grand Rapids community," said Dr. Slavin. He underscored his commitment to conducting high-quality research while ensuring that participants receive the same level of care and respect they expect from their regular healthcare providers.

Recognized as one of Grand Rapids' Top Doctors from 2021 through 2026 by Grand Rapids Magazine, Dr. Slavin's commitment to patient care and innovative research is evident in his professional background and community involvement.

Growth in Key Markets

The launch of the Grand Rapids site is in line with Headlands Research's ongoing growth across critical U.S. markets, having recently expanded its network to include additional sites like Headlands Research - Sacramento and Headlands Research - CTR-Lincoln. These expansions reflect the organization's strategic approach to enhancing its clinical research capabilities while maintaining expertise across various therapeutic areas.

With an impressive track record, having successfully completed over 5,000 clinical trials, Headlands Research is well-positioned to lead in advancing innovative medical therapies. The organization is dedicated to improving lives through research and provides access to a diverse participant population, allowing for more comprehensive and inclusive clinical studies.

For more information about Headlands Research and its new Grand Rapids site, visit www.headlandsresearch.com.